The FDA has cleared a treatment for New World screwworm (NWS) in dogs and cats under emergency use, expanding options for U.S. companion-animal practitioners who currently rely on extra-label protocols against the obligate mammalian parasite.

The action, reported by CIDRAP, targets Cochliomyia hominivorax — the only known screwworm fly whose larvae burrow through living tissue of warm-blooded hosts.

Until now, FDA-approved therapeutics for NWS in companion animals have been limited, leaving veterinarians and state animal-health officials to combine mechanical debridement, off-label parasiticide use, and quarantine.

What does the ruling change for clinics?

Under a CVM-issued emergency-use authorization, a product can be deployed before full approval when no adequate alternative exists for a serious or life-threatening condition. For day-one practice, the expected operational effects include:

• An FDA-recognized treatment option in dogs and cats where previously only extra-label regimens existed
• Distribution likely gated through state veterinarians or USDA-APHIS rather than standard pharmacy channels
• Mandatory reporting of adverse events and treatment outcomes attached to the authorization

Practitioners should consult their state veterinarian and the FDA-CVM emergency-use fact sheet before obtaining or administering the product.

Why dogs and cats, and why now?

NWS myiasis develops after a female fly oviposits on an open wound or mucous membrane. Larvae hatch within hours and consume living tissue, producing a foul odor and progressive wound enlargement. Untreated cases in dogs and cats are commonly fatal within 5 to 7 days.

The parasite was declared eradicated from the United States in 1966 via the sterile insect technique (SIT), in which mass-reared, irradiated male flies are released to mate with wild females. USDA-APHIS maintains that program, with a release buffer along the Mexican-Guatemalan border historically keeping C. hominivorax out of North America.

Companion animals have always been susceptible. Surveillance has concentrated on cattle, horses, and wildlife; a confirmed canine or feline case usually signals animal travel or importation from an endemic area. The recent northward spread of NWS detections through Central America has prompted USDA to expand sterile-fly production capacity as a defensive measure.

How do companion-animal, food-animal, and public-health implications split?

Companion animal: Dogs and cats imported from or traveling through endemic regions are the primary at-risk patients. Any non-healing wound in an animal with relevant travel history should prompt larval inspection.

Food animal: NWS control in U.S. cattle herds still depends on sterile-fly releases and active surveillance. The companion-animal authorization does not substitute for herd-level intervention.

Public health: C. hominivorax myiasis in people is rare but severe. An authorized veterinary product does not directly affect human risk, but companion-animal clinics are positioned as first detectors of any domestic re-introduction.

Open questions for the field

The CIDRAP notice disclosed neither the authorized compound, sponsor, dose range, target life stage, geographic scope, nor reporting endpoints — all of which will appear in the full FDA-CVM notice of authorization. The FDA docket should publish that document in the days ahead.